Skip to main content
  • One-Year BIOPACT Randomized Controlled Trial (RCT) Results Demonstrate Excellent Results for Low-Profile Passeo-18 Lux DCB

    Head-to-Head Non-Inferiority Study Shows Equivalent Safety and Efficacy of Passeo-18 Lux DCB to In.Pact Admiral DCB in Treatment of Femoropopliteal Lesions

    BIOTRONIK announced the presentation of one-year results from the investigator-initiated BIOPACT RCT this week by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2022 congress. The randomized controlled non-inferiority trial evaluated the safety and efficacy of the Passeo®-18 Lux® drug-coated balloon (DCB) catheter compared to the In.Pact Admiral DCB (Medtronic), and showed excellent results for both balloons through 12 months.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details